11 results on '"Oliansky DM"'
Search Results
2. Role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of pediatric acute lymphoblastic leukemia: update of the 2005 evidence-based review.
- Author
-
Oliansky DM, Camitta B, Gaynon P, Nieder ML, Parsons SK, Pulsipher MA, Dillon H, Ratko TA, Wall D, McCarthy PL Jr, and Hahn T
- Subjects
- Adolescent, Antineoplastic Agents administration & dosage, Child, Child, Preschool, Evidence-Based Medicine, Humans, Precursor Cell Lymphoblastic Leukemia-Lymphoma pathology, Recurrence, Remission Induction, Transplantation, Homologous, Treatment Outcome, Antineoplastic Agents therapeutic use, Combined Modality Therapy methods, Hematopoietic Stem Cell Transplantation, Precursor Cell Lymphoblastic Leukemia-Lymphoma therapy
- Abstract
Clinical research published since the first evidence-based review on the role of hematopoietic stem cell transplantation (SCT) in the treatment of pediatric acute lymphoblastic leukemia (ALL) is presented and critically evaluated in this update. Treatment recommendations are provided by an expert panel. Allogeneic SCT is recommended for children who: are in second complete remission (CR2) after experiencing an early marrow relapse for precursor-B ALL; experienced primary induction failure, but subsequently achieved a CR1; have T-lineage ALL in CR2; or have ALL in third or greater remission. Although the 2005 pediatric ALL evidence-based review (EBR) recommended allogeneic SCT for children with Philadelphia chromosome positive (Ph+) ALL in CR1, preliminary tyrosine kinase inhibitor (TKI) data demonstrate that early outcomes are comparable for allogeneic SCT and chemotherapy + imatinib. Based on the evidence, autologous SCT is not recommended for ALL in CR1. Allogeneic SCT is not recommended for: T-lineage ALL in CR1; mixed-lineage leukemia (MLL)+ ALL when it is the sole adverse risk factor; isolated central nervous system (CNS) relapse in precursor-B ALL. Based on expert opinion, allogeneic SCT may be considered for hypodiploid ALL and persistent minimal residual disease [corrected] (MRD) positivity in ALL in CR1 or greater, although these are areas that need further study. Treatment recommendations pertaining to various transplantation techniques are also provided, as are areas of needed future research., (Copyright © 2012 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.) more...
- Published
- 2012
- Full Text
- View/download PDF
Catalog
3. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of adult acute lymphoblastic leukemia: update of the 2006 evidence-based review.
- Author
-
Oliansky DM, Larson RA, Weisdorf D, Dillon H, Ratko TA, Wall D, McCarthy PL Jr, and Hahn T
- Subjects
- Combined Modality Therapy, Humans, Treatment Outcome, Hematopoietic Stem Cell Transplantation methods, Precursor Cell Lymphoblastic Leukemia-Lymphoma drug therapy, Precursor Cell Lymphoblastic Leukemia-Lymphoma surgery
- Published
- 2012
- Full Text
- View/download PDF
4. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of adult acute lymphoblastic leukemia: update of the 2006 evidence-based review.
- Author
-
Oliansky DM, Larson RA, Weisdorf D, Dillon H, Ratko TA, Wall D, McCarthy PL Jr, and Hahn T
- Subjects
- Evidence-Based Medicine, Humans, Hematopoietic Stem Cell Transplantation methods, Precursor Cell Lymphoblastic Leukemia-Lymphoma drug therapy, Precursor Cell Lymphoblastic Leukemia-Lymphoma surgery
- Abstract
Clinical research published since the first evidence-based review on the role of hematopoietic stem cell transplantation (SCT) in the treatment of acute lymphoblastic leukemia (ALL) in adults is presented and critically evaluated in this update. Treatment recommendations changed or modified based on new evidence include: (1) myeloablative allogeneic SCT is an appropriate treatment for adult (<35 years) ALL in first complete remission for all disease risk groups; and (2) reduced-intensity conditioning may produce similar outcomes to myeloablative regimens. Treatment recommendations unchanged or strengthened by new evidence include: (1) allogeneic SCT is recommended over chemotherapy for ALL in second complete remission or greater; (2) allogeneic is superior to autologous SCT; and (3) there are similar survival outcomes after related and unrelated allogeneic SCT. New treatment recommendations based on new evidence include: (1) in the absence of a suitable allogeneic donor, autologous SCT may be an appropriate therapy, but results in a high relapse rate; (2) it is appropriate to consider cord blood transplantation for patients with no HLA well-matched donor; and (3) imatinib therapy before and/or after SCT (for Ph+ ALL) yields significantly superior survival outcomes. Areas of needed research in the treatment of adult ALL with SCT were identified and presented in the review., (Copyright © 2012 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.) more...
- Published
- 2012
- Full Text
- View/download PDF
5. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of diffuse large B cell lymphoma: update of the 2001 evidence-based review.
- Author
-
Oliansky DM, Czuczman M, Fisher RI, Irwin FD, Lazarus HM, Omel J, Vose J, Wolff SN, Jones RB, McCarthy PL Jr, and Hahn T
- Subjects
- Combined Modality Therapy, Evidence-Based Medicine, Humans, Practice Guidelines as Topic, Cytotoxins therapeutic use, Hematopoietic Stem Cell Transplantation methods, Lymphoma, Large B-Cell, Diffuse therapy
- Abstract
Clinical research published since the 2001 evidence-based review on the role of hematopoietic stem cell transplantation (SCT) in the treatment of diffuse large B cell lymphoma (DLBCL) in adults is presented and critically evaluated in this update. Treatment recommendations that remain unchanged from the original review include: (1) autologous SCT as salvage therapy is recommended for patients with chemosensitive relapsed DLBCL; and (2) autologous SCT is not recommended for patients who achieve a partial response to an abbreviated induction regimen. New treatment recommendations based on new published data include: (1) autologous SCT as first-line therapy is not recommended for any IPI group; (2) planned tandem or multiple sequential autologous SCT is not recommended; (3) peripheral blood is the standard stem cell source for autologous SCT; (4) age is not a contraindication for autologous SCT, although outcomes in older adults are not as good as in younger adults. There are insufficient data to make recommendations on the routine use of rituximab maintenance after autologous SCT, autologous versus allogeneic SCT, fewer versus more cycles of induction therapy prior to autologous SCT, or the use of reduced intensity versus myeloablative conditioning regimens. Areas of needed research in the treatment of DLBCL with SCT were identified and are presented in the review., (2011 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.) more...
- Published
- 2011
- Full Text
- View/download PDF
6. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of follicular lymphoma: an evidence-based review.
- Author
-
Oliansky DM, Gordon LI, King J, Laport G, Leonard JP, McLaughlin P, Soiffer RJ, van Besien KW, Werner M, Jones RB, McCarthy PL Jr, and Hahn T
- Subjects
- Antibodies, Monoclonal administration & dosage, Antibodies, Monoclonal, Murine-Derived, Combined Modality Therapy, Evidence-Based Medicine, Humans, Lymphoma, Follicular drug therapy, Lymphoma, Follicular surgery, Prognosis, Rituximab, Transplantation Conditioning, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Hematopoietic Stem Cell Transplantation methods, Lymphoma, Follicular therapy
- Abstract
Clinical research examining the role of hematopoietic stem cell transplantation (SCT) in the therapy of follicular non-Hodgkin lymphoma in adults is presented and critically evaluated in this systematic evidence-based review. Specific criteria were used for searching the published literature and for grading the quality and strength of the evidence and the strength of the treatment recommendations. Treatment recommendations reached unanimously by a panel of follicular lymphoma experts are: (1) autologous SCT is recommended as salvage therapy based on pre-rituximab data, with a significant improvement in overall survival (OS) and progression-free (PFS) survival; (2) autologous SCT is not recommended as first-line treatment for most patients because of no significant improvement in OS; (3) autologous SCT is recommended for transformed follicular lymphoma patients; (4) reduced intensity conditioning before allogeneic SCT appears to be an acceptable alternative to myeloablative regimens; (5) an HLA-matched unrelated donor appears to be as effective an HLA-matched related donor for reduced intensity conditioning allogeneic SCT. There are insufficient data to make a recommendation on the use of autologous SCT after rituximab-based salvage therapy. Eleven areas of needed research in the treatment of follicular lymphoma with SCT were identified and are presented in the review., (Copyright (c) 2010 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.) more...
- Published
- 2010
- Full Text
- View/download PDF
7. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of myelodysplastic syndromes: an evidence-based review.
- Author
-
Oliansky DM, Antin JH, Bennett JM, Deeg HJ, Engelhardt C, Heptinstall KV, de Lima M, Gore SD, Potts RG, Silverman LR, Jones RB, McCarthy PL Jr, and Hahn T
- Subjects
- Antineoplastic Agents therapeutic use, Clinical Trials as Topic, Evidence-Based Medicine, Humans, Meta-Analysis as Topic, Myelodysplastic Syndromes diagnosis, Myelodysplastic Syndromes drug therapy, Prognosis, Severity of Illness Index, Hematopoietic Stem Cell Transplantation methods, Myelodysplastic Syndromes therapy
- Abstract
Clinical research examining the role of hematopoietic stem cell transplantation (SCT) in the therapy of myelodysplastic syndromes (MDS) in adults is presented and critically evaluated in this systematic evidence-based review. Specific criteria were used for searching the published literature and for grading the quality and strength of the evidence and the strength of the treatment recommendations. Treatment recommendations based on the evidence are presented in Table 3, and were reached unanimously by a panel of MDS experts. The identified priority areas of needed future research in MDS include: (1) the benefit of using alternative donor sources (eg, cord blood; haploidentical family donors) for patients without matched sibling or unrelated donors; (2) the role and appropriate timing of allogeneic SCT in combination with hypomethylating and immunomodulatory treatment regimens; (3) randomized trials comparing the safety and efficacy of various novel agents for treating MDS; and (4) the influence of the various MDS treatment modalities on patient-reported quality-of-life outcomes. more...
- Published
- 2009
- Full Text
- View/download PDF
8. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute myelogenous leukemia in adults: an evidence-based review.
- Author
-
Oliansky DM, Appelbaum F, Cassileth PA, Keating A, Kerr J, Nieto Y, Stewart S, Stone RM, Tallman MS, McCarthy PL Jr, and Hahn T
- Subjects
- Combined Modality Therapy, Evidence-Based Medicine, Humans, Nucleophosmin, PubMed, Antineoplastic Agents therapeutic use, Hematopoietic Stem Cell Transplantation methods, Leukemia, Myeloid, Acute therapy
- Abstract
Clinical research examining the role of hematopoietic stem cell transplantation (HSCT) in the therapy of acute myelogenous leukemia (AML) in adults is presented and critically evaluated in this systematic evidence-based review. Specific criteria were used for searching the published literature and for grading the quality and strength of the evidence and the strength of the treatment recommendations. Treatment recommendations based on the evidence are presented in Table 3, entitled Summary of Treatment Recommendations Made by the Expert Panel for Adult Acute Myelogenous Leukemia, and were reached unanimously by a panel of AML experts. The identified priority areas of needed future research in adult AML include: (1) What is the role of HSCT in treating patients with specific molecular markers (eg, FLT3, NPM1, CEBPA, BAALC, MLL, NRAS, etc.) especially in patients with normal cytogenetics? (2) What is the benefit of using HSCT to treat different cytogenetic subgroups? (3) What is the impact on survival outcomes of reduced intensity or nonmyeloablative versus conventional conditioning in older (>60 years) and intermediate (40-60 years) aged adults? (4) What is the impact on survival outcomes of unrelated donor HSCT vesus chemotherapy in younger (<40 years) adults with high risk disease? more...
- Published
- 2008
- Full Text
- View/download PDF
9. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute myeloid leukemia in children: an evidence-based review.
- Author
-
Oliansky DM, Rizzo JD, Aplan PD, Arceci RJ, Leone L, Ravindranath Y, Sanders JE, Smith FO 3rd, Wilmot F, McCarthy PL Jr, and Hahn T
- Subjects
- Acute Disease, Adolescent, Bone Marrow Transplantation, Child, Child, Preschool, Evidence-Based Medicine, Hematopoietic Stem Cell Transplantation adverse effects, Humans, Leukemia, Myeloid genetics, Leukemia, Myeloid, Acute genetics, Remission Induction methods, Transplantation Conditioning methods, Transplantation, Autologous, Transplantation, Homologous, Hematopoietic Stem Cell Transplantation methods, Leukemia, Myeloid therapy, Leukemia, Myeloid, Acute therapy
- Abstract
Clinical research examining the role of hematopoietic stem cell transplantation (SCT) in the therapy of acute myeloid leukemia (AML) in children is presented and critically evaluated in this systematic evidence-based review. Specific criteria were used for searching the published literature and for grading the quality and strength of the evidence and the strength of the treatment recommendations. Treatment recommendations based on the evidence are presented in the table entitled "Summary of Treatment Recommendations Made by the Expert Panel for Pediatric Acute Myeloid Leukemia" and were reached unanimously by a panel of experts in AML. The identified priority areas of needed future research in pediatric AML include: What is the role of risk group stratification, including the role of cytogenetics, in selection of patients for allogeneic SCT, especially those in first CR? What is the appropriate timing and use of alternative donor SCT, given that matched unrelated donor SCT appears to yield outcomes equivalent to matched related donor SCT? What is the role of reduced intensity SCT (including the use of fludarabine-based preparative regimens) and/or other immunomodulatory approaches to maximize the graft-versus-leukemic effect? and What is the role of biologically targeted agents (ie, tyrosine kinase inhibitors, farnesyl transferase inhibitors, Flt-3 inhibitors, etc) in the treatment of AML, including induction, consolidation, conditioning regimens, and after SCT? more...
- Published
- 2007
- Full Text
- View/download PDF
10. Subjective, social, and physical availability. II. Their simultaneous effects on alcohol consumption.
- Author
-
Abbey A, Scott RO, Oliansky DM, Quinn B, and Andreski PM
- Subjects
- Alcohol Drinking prevention & control, Alcoholism rehabilitation, Humans, Social Environment, Social Facilitation, Alcohol Drinking psychology, Alcoholism psychology, Internal-External Control
- Abstract
Part I of this (this journal, Vol. 25, No. 8, pp. 889-910) series described the theoretical justification for this research, the methods and measures used, and the interrelationships between indicators of physical, subjective, and social availability. Part II explores the relationships between these variables and alcohol consumption using bivariate analyses and structural equation modeling. As predicted, for these metropolitan residents, physical distance from an outlet only indirectly related to alcohol consumption via its negative relationship to subjective availability. Indicators of both subjective and social availability positively related to alcohol consumption. The implications of these results for future availability research and prevention programming are discussed. more...
- Published
- 1990
- Full Text
- View/download PDF
11. Subjective, social, and physical availability. I. Their interrelationships.
- Author
-
Abbey A, Scott RO, Oliansky DM, Quinn B, and Andreski PM
- Subjects
- Adult, Aged, Alcoholism psychology, Female, Humans, Male, Michigan, Middle Aged, Social Facilitation, Alcohol Drinking psychology, Alcoholic Beverages supply & distribution, Motivation, Social Environment
- Abstract
The alcohol availability literature suggests that physical conditions which restrict alcohol availability reduce rates of alcohol consumption. Smart (1980) argued that the availability construct should be expanded to include subjective and social components. It was hypothesized that people who perceived alcohol to be subjectively and socially available would consume more alcohol than those who did not and that physical availability would only indirectly affect consumption. These hypotheses were examined using data from a telephone survey. In Part I, the interrelationships between physical, subjective, and social availability are described. In Part II (this journal, Vol. 25, No. 9), the relationships between these variables and alcohol consumption are explored. more...
- Published
- 1990
- Full Text
- View/download PDF
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.